Tacrolimus induces short‐term but not long‐term clinical response in inflammatory bowel disease
Open Access
- 17 March 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (9), 870-879
- https://doi.org/10.1111/apt.15687
Abstract
Background Tacrolimus is a calcineurin inhibitor commonly used for prophylaxis of rejection in renal and liver transplantation. There are limited but favourable data regarding its possible use in patients with inflammatory bowel disease (IBD). Aims To evaluate the efficacy and safety of tacrolimus in patients with IBD in clinical practice. Methods We performed a retrospective, multicentre study in 22 centres in Spain. All adult patients who received oral tacrolimus for luminal or perianal IBD were included. Clinical response was assessed by Harvey‐Bradshaw index and partial Mayo score after 3 months. Perianal disease was evaluated by fistula drainage assessment. Results One hundred and forty‐three patients were included (mean age 38 years; 51% male; median disease duration 110 months). In ulcerative colitis (UC) (n = 58), the partial Mayo score decreased after 3 months from median 6 to 3 (P = 0.0001), whereas in Crohn's disease (CD) (n = 85), the Harvey‐Bradshaw index decreased after 3 months from median 9 to 7 (P = 0.011). In CD patients, blood tacrolimus concentrations during induction (>10 ng/mL vs P = 0.021). Finally, 120 patients (84%) discontinued tacrolimus, usually due to absence or loss of response. Three patients (2%) were subsequently diagnosed with cancer. The overall rate of surgery was 39%, with a 33% colectomy rate in UC. Conclusions Tacrolimus shows a clinical benefit in both CD and UC after 3 months of treatment, but its long‐term effectiveness and frequent adverse events remain relevant issues in clinical practice.Funding Information
- Biocruces Bizkaia Health Research Institute (INT-BC-2018-007)
This publication has 25 references indexed in Scilit:
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersJournal of Crohn's and Colitis, 2017
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical ManagementJournal of Crohn's and Colitis, 2016
- Tacrolimus for the prevention and treatment of rejection of solid organ transplantsExpert Review of Clinical Immunology, 2015
- PharmGKB summaryPharmacogenetics and Genomics, 2013
- Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitisInflammatory Bowel Diseases, 2012
- A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitisGut, 2006
- AGA technical review on perianal Crohn’s diseaseGastroenterology, 2003
- Tacrolimus for the treatment of fistulas in patients with crohn’s disease: a randomized, placebo-controlled trialGastroenterology, 2003
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisThe New England Journal of Medicine, 1987
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980